30.35

3.94% 1.15

After Hours: 29.75 -0.60 -1.98%

Parabilis Medicines Inc (PBLS)

Overview News Price History Discussions Forecast

Parabilis Medicines Inc stock is traded at $30.35, with a volume of 507.96K. It is up +3.94% in the last 24 hours and up +0.00% over the past month. Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Previous Close:

$29.20

Open:

$29.45

24h Volume:

507.96K

Relative Volume:

2.05

Market Cap:

$3.71B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+10.89%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$28.39

$31.51

1-Week Range:

$26.68

$31.51

52-Week Range:

$24.51

$34.47

Parabilis Medicines Inc Stock (PBLS) Company Profile

Name

Parabilis Medicines Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

PBLS's Discussions on Twitter

Compare PBLS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBLS Parabilis Medicines Inc	30.35	3.57B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Parabilis Medicines Inc Stock (PBLS) Latest News

Jul 06, 2026

Leerink Partners Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $40 - Moomoo

Jul 06, 2026

Leerink initiates Parabilis Medicines stock with Outperform rating By Investing.com - Investing.com South Africa

Jul 06, 2026

The biggest biotech funding rounds in June 2026 - Labiotech.eu

Jul 06, 2026

PBLS Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus

Jul 06, 2026

Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway - TipRanks

Jul 06, 2026

Michael Schmidt Initiates Buy on Parabilis Medicines, Citing Helicon Platform and Zolucatetide as Key Value Drivers with $40 Price Target - TipRanks

Jul 06, 2026

BofA Securities initiates Parabilis Medicines stock coverage with buy rating - Investing.com

Jul 06, 2026

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jul 06, 2026

Guggenheim initiates Parabilis Medicines stock with buy rating - Investing.com

Jul 06, 2026

Jul 04, 2026

PBLS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI

Jul 04, 2026

Jul 02, 2026